Charter Research & Investment Group Inc. Decreases Stake in Pfizer Inc. (NYSE:PFE)

Charter Research & Investment Group Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 11,828 shares of the biopharmaceutical company’s stock after selling 2,258 shares during the quarter. Charter Research & Investment Group Inc.’s holdings in Pfizer were worth $314,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in PFE. PSI Advisors LLC boosted its position in Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. lifted its position in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton boosted its holdings in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its stake in shares of Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 401 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on PFE. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.8 %

Shares of NYSE PFE opened at $25.20 on Friday. The stock has a market cap of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a 50-day moving average of $26.06 and a 200 day moving average of $26.92.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.